Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $138,389 | $157,748 | $205,755 | $12,359 |
| % Growth | -12.3% | -23.3% | 1,564.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $138,389 | $157,748 | $205,755 | $12,359 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $195,156 | $192,133 | $147,751 | $173,760 |
| G&A Expenses | $52,823 | $52,871 | $46,071 | $41,451 |
| SG&A Expenses | $52,823 | $52,871 | $46,071 | $41,451 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$13,921 | -$9,051 | -$244 | $0 |
| Operating Expenses | $234,058 | $235,953 | $193,578 | $215,211 |
| Operating Income | -$95,669 | -$78,205 | $12,177 | -$202,852 |
| % Margin | -69.1% | -49.6% | 5.9% | -1,641.3% |
| Other Income/Exp. Net | $14,724 | $50,315 | -$1,533 | -$822 |
| Pre-Tax Income | -$80,945 | -$27,890 | $10,644 | -$203,674 |
| Tax Expense | -$4 | $1,835 | $1,295 | $0 |
| Net Income | -$80,941 | -$29,725 | $9,349 | -$203,674 |
| % Margin | -58.5% | -18.8% | 4.5% | -1,648% |
| EPS | -3 | -1.12 | 0.35 | -7.74 |
| % Growth | -167.9% | -420% | 104.5% | – |
| EPS Diluted | -3 | -1.12 | 0.35 | -7.74 |
| Weighted Avg Shares Out | 27,000 | 26,628 | 26,445 | 26,317 |
| Weighted Avg Shares Out Dil | 27,000 | 26,628 | 27,093 | 26,317 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,195 | $17,359 | $2,581 | $753 |
| Interest Expense | $0 | $767 | $3,001 | $2,674 |
| Depreciation & Amortization | $3,544 | $2,957 | $1,527 | $1,193 |
| EBITDA | -$77,401 | -$24,165 | $13,704 | -$201,659 |
| % Margin | -55.9% | -15.3% | 6.7% | -1,631.7% |